Perfuze
Neurovascular medical device company developing technology for Ischemic Stroke
Neurovascular medical device company developing technology for Ischemic Stroke
Perfuze is a neurovascular medical device company founded in 2018 and based in Ireland. The company's slogan focuses on developing technology for Ischemic Stroke, a critical area within the biotechnology, healthcare, and medical devices industries.
Perfuze recently secured a significant €22.50M Series A investment on 09 February 2022, with participation from notable investors including Earlybird, SV Health Investors, Seroba Life Sciences, HBM-MedFocus, LSP Health Economics Fund, EQT Life Sciences, and Medtech Convergence Fund.
As a promising player in the neurovascular medtech startup landscape, Perfuze's recent funding round is a testament to the confidence of prominent investors in the company's innovative approach to addressing Ischemic Stroke. This infusion of capital is expected to fuel the company's growth and advance its mission of developing impactful medical solutions in the neurovascular space.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €22.50M | 7 |
|
09 Feb 2022 |
| Seed Round | €3.00M | 3 |
|
29 Jan 2019 |
No recent news or press coverage available for Perfuze.
We care about your data, and we'd love to use cookies make your experience better.
